Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The success of Eli Lilly’s Zepbound, a challenger to Novo’s Wegovy, has prompted comparisons to a similar scenario, when ...

A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...

An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

Eli Lilly & Co. closed $48.10 short of its 52-week high ($972.53), which the company achieved on August 22nd.

To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.

Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...

On Thursday, Eli Lilly And Co (LLY) stock saw a decline, ending the day at $909.32 which represents a decrease of $-15.24 or -1.65% from the prior close of $924.56. The stock opened at $920.26 and ...

With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

Eli Lilly has received approval in Japan for Kisunla (donanemab-azbt) to treat early symptomatic Alzheimer's disease.